CN1155388C - 利巴韦林口服固体剂型及其制备方法 - Google Patents

利巴韦林口服固体剂型及其制备方法 Download PDF

Info

Publication number
CN1155388C
CN1155388C CNB988124858A CN98812485A CN1155388C CN 1155388 C CN1155388 C CN 1155388C CN B988124858 A CNB988124858 A CN B988124858A CN 98812485 A CN98812485 A CN 98812485A CN 1155388 C CN1155388 C CN 1155388C
Authority
CN
China
Prior art keywords
ribavirin
composition
dosage form
compressed
solid dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988124858A
Other languages
English (en)
Chinese (zh)
Other versions
CN1283117A (zh
Inventor
S��M����ά˹
S·M·利波维茨
E·I·斯图帕克
�Ф
I·A·肖德赖
��˹��ŵ��
W·A·瓦迪诺
F·E·波文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27130673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1155388(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/997,169 external-priority patent/US5916594A/en
Priority claimed from US08/997,172 external-priority patent/US5914128A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1283117A publication Critical patent/CN1283117A/zh
Application granted granted Critical
Publication of CN1155388C publication Critical patent/CN1155388C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB988124858A 1997-12-22 1998-12-21 利巴韦林口服固体剂型及其制备方法 Expired - Fee Related CN1155388C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/997,169 US5916594A (en) 1997-12-22 1997-12-22 Process of making solid ribavirin dosage forms
US08/997,172 US5914128A (en) 1997-12-22 1997-12-22 Orally administrable solid dosage form
US08/997,172 1997-12-22
US08/997,169 1997-12-22
US08/997169 1997-12-22
US08/997172 1997-12-22

Publications (2)

Publication Number Publication Date
CN1283117A CN1283117A (zh) 2001-02-07
CN1155388C true CN1155388C (zh) 2004-06-30

Family

ID=27130673

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988124858A Expired - Fee Related CN1155388C (zh) 1997-12-22 1998-12-21 利巴韦林口服固体剂型及其制备方法

Country Status (26)

Country Link
US (3) US6337090B1 (enExample)
EP (2) EP0991415B1 (enExample)
JP (2) JP2001526234A (enExample)
KR (1) KR100575389B1 (enExample)
CN (1) CN1155388C (enExample)
AR (1) AR008977A1 (enExample)
AT (1) ATE234103T1 (enExample)
AU (1) AU762826B2 (enExample)
BR (1) BR9814367A (enExample)
CA (4) CA2365412C (enExample)
CO (1) CO4970774A1 (enExample)
DE (1) DE69812094T2 (enExample)
DK (1) DK0991415T3 (enExample)
ES (1) ES2191987T3 (enExample)
HU (1) HUP0100433A3 (enExample)
IL (1) IL136549A (enExample)
MY (1) MY119656A (enExample)
NO (1) NO20003234L (enExample)
NZ (1) NZ504994A (enExample)
PE (1) PE20000066A1 (enExample)
PL (1) PL190267B1 (enExample)
PT (1) PT991415E (enExample)
SK (1) SK284520B6 (enExample)
TW (1) TW575436B (enExample)
WO (1) WO1999032128A1 (enExample)
ZA (1) ZA9811726B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE234103T1 (de) * 1997-12-22 2003-03-15 Schering Corp Feste, oral verabreichbare ribavirin dosisformen und verfahren zu deren herstellung
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
EP1263341B1 (en) * 2000-03-06 2008-06-11 Salient Surgical Technologies, Inc. Fluid delivery system and controller for electrosurgical devices
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
KR20030020137A (ko) * 2001-09-03 2003-03-08 진양제약주식회사 리바비린 건조시럽제
RU2004116821A (ru) * 2001-11-02 2005-04-20 Сандоз Инк. (Us) Способ получения быстрорастворимой композиции с высоким содержанием рибавирина
DE10227148A1 (de) * 2002-06-18 2004-01-08 Biopartners Gmbh Verwendung von Ribavirin zur Herstellung einer pharmazeutischen Zusammensetzung gegen Bunyaviridae
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
US20040142903A1 (en) * 2003-01-16 2004-07-22 Par Pharmaceutical Inc. Bioavailable fenofibrate compositions, methods for treating hyperlipidemia and hypercholesterolemia and processes for the preparation of such compositions
CN1980678A (zh) * 2003-03-28 2007-06-13 法莫赛特股份有限公司 治疗黄病毒感染的化合物
TR200701424T1 (tr) * 2004-09-09 2007-04-24 Bayer Healthcare Ag Suda çözünebilen katı dozaj formunda farmasötik bileşim.
US7723310B2 (en) * 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
US8062670B2 (en) * 2005-08-05 2011-11-22 3M Innovative Properties Company Compositions exhibiting improved flowability
EP2054076A2 (en) * 2006-08-21 2009-05-06 United Therapeutics Corporation Combination therapy for treatment of viral infections
WO2009142852A2 (en) * 2008-05-22 2009-11-26 3M Innovative Properties Company Process for manufacturing flowable powder drug compositions
WO2009158300A1 (en) * 2008-06-26 2009-12-30 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
EP2309984B1 (en) * 2008-07-02 2018-04-11 3M Innovative Properties Company Method of making a dry powder pharmaceutical composition
EP2295037A1 (en) 2009-09-11 2011-03-16 Ratiopharm GmbH Pharmaceutical formulation containing Ribavirin
US10363453B2 (en) 2011-02-07 2019-07-30 New Balance Athletics, Inc. Systems and methods for monitoring athletic and physiological performance
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
CN106389363A (zh) * 2016-10-18 2017-02-15 广东肇庆星湖生物科技股份有限公司 一种利巴韦林口服固体制剂及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1228029C2 (de) * 1964-05-09 1973-05-17 Merck Ag E Verfahren zur Herstellung von Tabletten durch Pressen von Pulvergemischen ohne vorhergehende Granulation
US3490742A (en) * 1966-01-14 1970-01-20 Staley Mfg Co A E Compressed tablets
US3622677A (en) * 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
DE2735600A1 (de) * 1977-08-06 1979-02-15 Dynamit Nobel Ag Verfahren zur herstellung von phthalid
JPS57146593A (en) * 1981-03-09 1982-09-10 Ajinomoto Co Inc Preparation of ribofuranosyltriazole derivative
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4681765A (en) * 1984-09-13 1987-07-21 American Home Products Corporation Rapid releasing triamterene containing gelatin capsule dosage forms for once daily antihypertensive use
US5077279A (en) * 1986-05-01 1991-12-31 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
US5084445A (en) * 1986-05-01 1992-01-28 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxy-5-methylcytidine
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
JPS63216820A (ja) * 1987-03-05 1988-09-09 Chugai Pharmaceut Co Ltd 抗ウイルス剤
GB8800276D0 (en) * 1988-01-07 1988-02-10 Univ Liverpool Medical treatment
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5192788A (en) * 1988-05-23 1993-03-09 Georgia State University Foundation, Inc. Porphyrin antiviral compositions
US5109016A (en) * 1988-05-23 1992-04-28 Georgia State University Foundation, Inc. Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
US5122517A (en) * 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
JP2908844B2 (ja) * 1990-06-29 1999-06-21 ヤマサ醤油株式会社 抗ウイルス剤
JPH07502740A (ja) * 1992-01-06 1995-03-23 ザ・ウエルカム・ファウンデーション・リミテッド 治療用ヌクレオシド
US5869097A (en) * 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
JPH06298665A (ja) * 1993-04-14 1994-10-25 Toray Ind Inc 抗ウイルス剤
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5492692A (en) * 1993-08-17 1996-02-20 University Of Kentucky Research Foundation Coated products with potent anti-HIV and antimicrobial properties
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
CA2135669A1 (en) 1994-11-10 1996-05-11 Nils O. Johannesson Ribavirin as hepato (liver) protecting agent
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
CA2213700C (en) * 1995-02-28 2002-04-02 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US5723589A (en) * 1995-12-21 1998-03-03 Icn Pharmaceuticals Carbohydrate conjugated bio-active compounds
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
ATE234103T1 (de) * 1997-12-22 2003-03-15 Schering Corp Feste, oral verabreichbare ribavirin dosisformen und verfahren zu deren herstellung

Also Published As

Publication number Publication date
NO20003234D0 (no) 2000-06-21
HUP0100433A3 (en) 2003-01-28
CA2323849C (en) 2002-06-11
AR008977A1 (es) 2000-03-08
US6051252A (en) 2000-04-18
CA2287056C (en) 2000-08-15
EP1321147A1 (en) 2003-06-25
KR20010033441A (ko) 2001-04-25
BR9814367A (pt) 2000-10-17
PL190267B1 (pl) 2005-11-30
AU762826B2 (en) 2003-07-03
DK0991415T3 (da) 2003-06-16
CA2365412C (en) 2002-09-17
CA2365412A1 (en) 1999-07-01
KR100575389B1 (ko) 2006-05-03
AU2199199A (en) 1999-07-12
DE69812094D1 (de) 2003-04-17
HUP0100433A2 (hu) 2001-12-28
ZA9811726B (en) 1999-06-21
ES2191987T3 (es) 2003-09-16
HK1034674A1 (en) 2001-11-02
ATE234103T1 (de) 2003-03-15
TW575436B (en) 2004-02-11
PT991415E (pt) 2003-06-30
CA2300452C (en) 2000-11-28
DE69812094T2 (de) 2003-12-24
SK284520B6 (sk) 2005-05-05
IL136549A0 (en) 2001-06-14
US6337090B1 (en) 2002-01-08
JP2006083189A (ja) 2006-03-30
EP0991415A1 (en) 2000-04-12
PE20000066A1 (es) 2000-02-09
NO20003234L (no) 2000-08-21
MY119656A (en) 2005-06-30
CA2323849A1 (en) 1999-07-01
PL341230A1 (en) 2001-03-26
CO4970774A1 (es) 2000-11-07
JP2001526234A (ja) 2001-12-18
CA2287056A1 (en) 1999-07-01
NZ504994A (en) 2002-10-25
US6335032B1 (en) 2002-01-01
CA2300452A1 (en) 1999-07-01
EP0991415B1 (en) 2003-03-12
SK8942000A3 (en) 2001-04-09
WO1999032128A1 (en) 1999-07-01
IL136549A (en) 2005-05-17
CN1283117A (zh) 2001-02-07

Similar Documents

Publication Publication Date Title
CN1155388C (zh) 利巴韦林口服固体剂型及其制备方法
CN1146419C (zh) 采用超级崩解剂的速溶依法维伦兹胶囊或片剂的制剂
CN1215833C (zh) 快速崩解的甲基纤维素片剂
CN1240374C (zh) 快速崩解的甲基纤维素片剂
CN1446089A (zh) 含有西酞普兰的药物组合物
US5914128A (en) Orally administrable solid dosage form
CN1147295C (zh) 包含托芬那酸或其医药可接受盐的快速释出片剂及其制法
CN87101974A (zh) 治疗剂
CN1684681A (zh) 比西发定制剂
CN1269474C (zh) 可压缩的愈创甘油醚组合物及其制备方法
HK1034674B (en) Orally administrable solid ribavirin dosage forms and process for making them
CN1303990C (zh) 阿魏酸钠口腔崩解片及其制备工艺
US5916594A (en) Process of making solid ribavirin dosage forms
CN1484523A (zh) 包含西酞普兰的药物组合物
CN1546010A (zh) 盐酸班布特罗口腔崩解片及其制备方法
CN1943561A (zh) 普卢利沙星口腔崩解片及其制备方法
CN1887277A (zh) 含有降血脂成分的分散片及其制备方法
CN1296045C (zh) 二氢麦角碱及其衍生物的口腔崩解片及其制备工艺
AU742943B2 (en) Orally administrable solid ribavirin dosage forms and process for making them
CN1907280A (zh) 马来酸左旋氨氯地平分散片及其制备方法
CN1634079A (zh) 一种复方戊酸雌二醇片及其制备方法
CN1817341A (zh) 米格列奈固体缓释制剂及其制备方法
CN1686122A (zh) 马来酸左旋氨氯地平口腔崩解片及其制备方法
HK1061641B (en) Antacid and laxative tablets
HK1065254A (en) Compaction process for manufacture of sodium phenytoin dosage form

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040630

Termination date: 20111221